CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase Ia study of Atezolizumab (NCT01375842) monotherapy in relapsed endometrial cancer were reported as abstract at ASCO 2017. Fif...
Phase 3
Barcelona, Spain and 92 other locations
study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial...
Phase 3
Badalona, Spain and 83 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Barcelona, Spain and 218 other locations
for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...
Phase 3
Barcelona, Spain and 77 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Barcelona, Spain and 202 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Barcelona, Spain and 82 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Barcelona, Spain and 162 other locations
choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...
Phase 3
Barcelona, Spain and 168 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Barcelona, Spain and 73 other locations
who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, e....
Phase 1
Barcelona, Spain and 21 other locations
Clinical trials
Research sites
Resources
Legal